Wisconsin Collaborative for Quality Healthcare

View Our Reports

print this page

Population Focus


The results below represent the entire WCHQ population (all providers, total population) for all WCHQ Ambulatory Care measures. Click the historical data links to see how the WCHQ population is improving over time.

Chronic Care
Diabetes: Blood Sugar (A1c) Testing 
N=214,075
View Historical Data
N=214,075
View Historical Data
Diabetes: Kidney Function Monitored 
N=214,075
View Historical Data
95.72%
95.72%
Diabetes: Blood Pressure Control 
N=214,075
View Historical Data
83.40%
83.40%
N=29,703
View Historical Data
96.90%
96.90%
Diabetes: Statin Use Unless Contraindicated 
N=197,543
View Historical Data
82.78%
82.78%
N=208,829
View Historical Data
84.86%
84.86%
Diabetes: All-or-None Process Measure (Optimal Testing) Diabetes All-or-None Measures. The Diabetes All-or-None Measure contains two goals. Both goals within the measure must be reached by each patient in order to meet the measure. Diabetes optimal testing includes: * Two A1C tests performed during the 12 month reporting period AND * One kidney function test during the 12 month reporting period, and/or diagnosis and treatment of kidney disease. Why use an All-or-None method? This method was chosen because of the benefits it provides to both the patient and the provider. For the Patient: The American Diabetes Association recommends these two tests to prevent and reduce diabetes complications such as blindness, loss of limb and kidney disease. Both tests should be performed and the test results will help your doctor decide the best diabetes care for you. The All-or-None measure can be used to see how well diabetes care is done where you receive your care. For the Provider: This method represents a systems perspective emphasizing the importance of optimal care through a patients entire healthcare experience. In addition, this method gives a more sensitive scale for improvement. For those organizations scoring high marks on individual measures, the All-or-None measure will give room for benchmarks and additional improvements to be made.
N=213,294
View Historical Data
75.07%
75.07%
Diabetes: All-or-None Outcome Measure (Optimal Control)  Diabetes All-or-None Measures. The Diabetes All-or-None Measures are two separate measures, one for process (optimal testing) and one for outcomes (optimal results). Each measure contains three goals. All three goals within a measure must be reached in order to meet that measure. The numerator of each all-or-none measure is collected from the organizations total diabetes denominator. Using the diabetes denominator optimal results includes: * Most recent A1C test result is less than than 8.0% AND * Most recent blood pressure measurement is less than 140/90 mm Hg AND * Tobacco Non-User AND * Daily Aspirin or Other Antiplatelet for Diabetes Patients with Ischemic Vascular Disease Unless Contraindicated AND * Statin Use for patients ages 40 through 75 or patients with IVD of any age. Why use an All-or-None method? This method was chosen because of the benefits it provides to both the patient and the practitioner. First, this methodology more closely reflects the interests and likely desires of the patient. With the data collected in two scores (optimal testing and optimal results), patients can easily look and see how their provider group is performing on these criteria rather than trying to make sense of multiple scores on individual measures. Second, this method represents a systems perspective emphasizing the importance of optimal care through a patients entire healthcare experience. Third, this method gives a more sensitive scale for improvement. For those organizations scoring high marks on individual measures, the All-or-None measure will give room for benchmarks and additional improvements to be made. Nolan T, Berwick DM. All-or-none measurement raises the bar on performance. JAMA. 2006 Mar 8;295(10):1168-70.
N=207,583
View Historical Data
44.55%
44.55%
Controlling High Blood Pressure: Blood Pressure Control Hypertension (high blood pressure) affects approximately 50 million individuals in the United States. "Essential Hypertension" is diagnosed when no specific cause for the elevated blood pressure can be found. A normal blood pressure for most adults is less than 120/80 mm Hg. High blood pressure is a leading risk factor for coronary heart disease, congestive heart failure, renal disease and stroke. Controlling one's blood pressure can help prevent these diseases. This measure assesses the percentage of patients 18-85 years of age who have a diagnosis of essential hypertension and whose blood pressure was adequately controlled based on the the eighth report of the Joint National Committee treatment goals of: *Less than 140/90 for patients less than 60 years of age or patients of any age with a diagnosis of diabetes and/or chronic kidney disease. *Less than 150/90 for patients 60 years of age and older without diabetes or chronic kidney disease.
N=600,081
View Historical Data
83.87%
83.87%
Ischemic Vascular Disease: Daily Aspirin or Other Antiplatelet Therapy Unless Contraindicated There has been important evidence from clinical trials that further supports and broadens the merits of risk-reduction therapies for patients with established coronary and other atherosclerotic vascular disease, including peripheral arterial disease, atherosclerotic aortic disease, and carotid artery disease. Based on trials involving other secondary prevention therapies, the ACC and AHA recommends aspirin in all patients, unless contraindicated, with established coronary and other atherosclerotic vascular disease, including peripheral arterial disease, atherosclerotic aortic disease, and carotid artery disease. The ACC and AHA also recommend the use of other antiplatelet agents based on disease type and clinical conditions. This measure shows the percentage of people 18 to 75 years of age with a diagnosis coronary or other atherosclerotic vascular disease who were prescribed oral antiplatelet therapy, unless contraindicated, in the measurement year.
N=86,410
View Historical Data
95.67%
95.67%
Ischemic Vascular Disease: All-or-None Outcome Measure (Optimal Control)  The IVD All-or-None Measure is one outcome measure (optimal control). The measure contains four goals. All four goals within a measure must be reached in order to meet that measure. The numerator for the all-or-none measure should be collected from the organization's total IVD denominator.All-or-None Outcome Measure (Optimal Control) - Using the IVD denominator optimal results include: * Most recent blood pressure measurement is less than 140/90 mm Hg -- And * Most recent tobacco status is Tobacco Free -- And * Daily Aspirin or Other Antiplatelet Unless Contraindicated -- And * Statin Use. Why use an All-or-None method? This method was chosen because of the benefits it provides to both the patient and the practitioner. First, this methodology more closely reflects the interests and likely desires of the patient. With the data collected in two scores (optimal testing and optimal results), patients can easily look and see how their provider group is performing on these criteria rather than trying to make sense of multiple scores on individual measures. Second, this method represents a systems perspective emphasizing the importance of optimal care through a patient's entire healthcare experience. Third, this method gives a more sensitive scale for improvement. For those organizations scoring high marks on individual measures, the All-or-None measure will give room for benchmarks and additional improvements to be made.
N=84,847
View Historical Data
63.62%
63.62%
Ischemic Vascular Disease: Blood Pressure Control There has been important evidence from clinical trials that further supports and broadens the merits of risk-reduction therapies for patients with established coronary and other atherosclerotic vascular disease, including peripheral arterial disease, atherosclerotic aortic disease, and carotid artery disease. The American College of Cardiology (ACC) and the American Heart Association (AHA) recommends that a blood pressure is measured at every routine visit and that the systolic blood pressure is less than 140 mmHg and the diastolic blood pressure is less than 90 mmHg. This measure shows the percentage of people 18-75 years of age with a diagnosis of IVD whose most recent blood pressure reading within the measurement period is controlled to a rate of less than 140/90 mmHg.
N=87,024
View Historical Data
84.44%
84.44%
N=85,300
View Historical Data
82.84%
82.84%
Ischemic Vascular Disease: Statin Use Unless Contraindicated The American College of Cardiology (ACC) and the American Heart Association (AHA) recommends that high-intensity statin therapy should be initiated or continued as first-line therapy in women and men less than or equal to 75 years of age who have clinical atherosclerotic cardiovascular disease, unless contraindicated. In November 2013, the ACC and AHA Task Force on Practice Guidelines released updated guidance for the treatment of blood cholesterol. The new recommendations remove treatment targets for LDL-C for the primary or secondary prevention of atherosclerotic cardiovascular disease (ASCVD) and recommend high or moderate intensity statin therapy based on patient risk factors. Four major statin benefit groups were identified and iIndividuals with ASCVD are one of the identified groups.
N=86,410
View Historical Data
93.45%
93.45%
Preventive Care
Adolescent Immunization Status For the general community, high childhood immunization rates prevent the resurgence of many infectious diseases, such as polio, that have been virtually eradicated from most developed countries (CDC, 1999). The general clinical consensus is that if immunization practices ceased, most infectious and contagious diseases currently prevented by vaccinations would reemerge as lethal health threats. Potential for exposure to infectious disease is even greater with the increase in international travel. By ensuring proper immunization of adolescents, organizations can help contain the transmission of these diseases and help protect the general population. This measure assesses the percentage of adolescents who had each of the following immunizations by their 13th birthday: One dose of meningococcal vaccine AND, One tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) OR, One tetanus, diphtheria toxoids vaccine (Td)
N=26,463
View Historical Data
82.33%
82.33%
Adult Body Mass Index (BMI) Control The United States Preventive Services Task Force (USPSTF) Guide to Clinical Preventive Services, June 2012, recommends that clinicians screen all adult patients for obesity and offer intensive counseling and behavioral interventions to promote sustained weight loss for obese adults. In addition, the Institute for Clinical Systems Improvement (ICSI, 2011) Prevention and Management of Obesity (Mature Adolescents and Adults) provides the following guidance: *Calculate the body mass index; classify the individual based on the body mass index categories. Educate patients about their body mass index and their associated risks. *Weight management requires a team approach. Be aware of clinical and community resources. The patient needs to have an ongoing therapeutic relationship and follow-up with a health care team. *Weight control is a lifelong commitment, and the health care team can assist with setting specific goals with the patient.BMI Parameters: *Normal Parameters: 18-64 years BMI >=18.5 and <25, 65 years and older BMI >=23 and <30 *Above Normal Parameters: 18-64 years BMI >=25, 65 years and older BMI >=30 *Below Normal Parameters: 18-64 years BMI <18.5, 65 years and older BMI<23
N=1,755,398
View Historical Data
Adult Body Mass Index (BMI) Screening Annually The United States Preventive Services Task Force (USPSTF) Guide to Clinical Preventive Services, June 2012, recommends that clinicians screen all adult patients for obesity and offer intensive counseling and behavioral interventions to promote sustained weight loss for obese adults.

In addition, the Institute for Clinical Systems Improvement (ICSI, 2011) Prevention and Management of Obesity (Mature Adolescents and Adults) provides the following guidance: *Calculate the body mass index; classify the individual based on the body mass index categories. Educate patients about their body mass index and their associated risks. *Weight management requires a team approach. Be aware of clinical and community resources. The patient needs to have an ongoing therapeutic relationship and follow-up with a health care team. *Weight control is a lifelong commitment, and the health care team can assist with setting specific goals with the patient.

This measure assesses adults ages 18 through 85 who have had a minimum of one BMI Test annually.
N=1,792,313
View Historical Data
97.38%
97.38%
Breast Cancer Screening There is convincing evidence that screening with film mammography reduces breast cancer mortality, with a greater absolute reduction for women aged 50 to 74 years than for women aged 40 to 49 years. The strongest evidence for the greatest benefit is among women aged 60 to 69 years. Among women 75 years or older, evidence of benefits of mammography is lacking.Recommended intervals for mammography screening may also vary on an individual basis, but there is a general consensus that every two years is the minimum frequency. However, it is recommended that women speak with their health care providers to determine on an individual basis the age at which to begin and end mammography screening and the frequency of these screenings. For women who have had sporadic breast cancer the evidence supports regular history, physical examination, and mammography as the cornerstone of appropriate breast cancer follow-up. Women treated with breast-conserving therapy should have their first post-treatment mammogram no earlier than 6 months after definitive radiation therapy. Subsequent mammograms should be obtained every 6 to 12 months for surveillance of abnormalities. Mammography should be performed yearly if stability of mammographic findings is achieved after completion of loco regional therapy.This measure assesses the percentage of women age 50 through 74 who had a minimum of one breast cancer screening test during the two year measurement period
N=550,955
View Historical Data
78.98%
78.98%
Cervical Cancer Screening 
N=793,256
View Historical Data
80.52%
80.52%
Childhood Immunization Status For the general community, high childhood immunization rates prevent the resurgence of many infectious diseases, such as polio, that have been virtually eradicated from most developed countries (CDC, 1999). The general clinical consensus is that if immunization practices ceased, most infectious and contagious diseases currently prevented by vaccinations would reemerge as lethal health threats. Potential for exposure to infectious disease is even greater with the increase in international travel. By ensuring proper immunization of children by the age of two, health organizations can help contain the transmission of these diseases and help protect the general population. This measure assesses completion of the Primary Childhood Series for children age two who have had each of the following immunizations: *Four Diphtheria Tetanus and Acellular Pertussis (DTaP) *Three Polio (IPV) *One Measles, Mumps and Rubella (MMR) *Three H influenza Type B (HiB) *Three Hepatitis B (Hep B) *One Chicken Pox/Varicella (VZV) *Four Pneumococcal Conjugate (PCV)
N=38,463
View Historical Data
80.25%
80.25%
Chlamydia Screening in Women 
N=65,529
42.26%
42.26%
Colorectal Cancer Screening 
N=1,073,248
View Historical Data
77.26%
77.26%
Screening For Clinical Depression 
N=1,266,253
View Historical Data
43.72%
43.72%
Screening for Osteoporosis 
N=306,259
View Historical Data
84.13%
84.13%
Well Child Visit First 15 Months of Life This measure is based on the CMS and American Academy of Pediatrics guidelines for Early and Periodic Screening, Diagnostic and Treatment (EPSDT) visits which outlines the following benefits of Well-Child Visits: *Prevention. Your child gets scheduled immunizations to prevent illness. You also can ask your pediatrician about nutrition and safety in the home and at school. *Tracking growth and development. See how much your child has grown in the time since your last visit, and talk with your doctor about your childs development. You can discuss your childs milestones, social behaviors and learning. *Raising concerns. Make a list of topics you want to talk about with your childs pediatrician such as development, behavior, sleep, eating or getting along with other family members. Bring your top three to five questions or concerns with you to talk with your pediatrician at the start of the visit. *Team approach. Regular visits create strong, trustworthy relationships among pediatrician, parent and child. The AAP recommends well-child visits as a way for pediatricians and parents to serve the needs of children. This team approach helps develop optimal physical, mental and social health of a child. * It is recommended that visits in the first 15 months of life occur at the following ages: By 1 month, 2 months, 4 months, 6 months, 9 months, 12 months and 15 months.

This measure assesses the percentage of pediatric patients who turned 15 months old during the measurement period and who had six or more well-child visits with a PCP during their first 15 months of life (by their 15 month birthday).
N=39,900
71.53%
71.53%
Adults with Pneumococcal Vaccinations 
N=600,514
View Historical Data
88.97%
88.97%
Tobacco User Receiving Tobacco Cessation Advice 
N=262,010
View Historical Data
90.51%
90.51%